Q-omics provides the consensus-scored FKBP7 profile across patient tissues and cancer cell-line models. FKBP7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FKBP7 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FKBP7 protein abundance shows 32,724 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, HNSC, and LSCC as cancer lineages where FKBP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP7 survival associations across molecular data types. FKBP7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP7 RNA expression–survival associations across cancer types. High FKBP7 expression shows unfavorable associations in UVM, STAD, KIRP, CESC, ACC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FKBP7 RNA expression.
This table summarizes FKBP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FKBP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP7 shows lower tumor expression in KICH, THCA, UCEC and BLCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher FKBP7 RNA expression in tumor versus normal tissue (log2 FC = +0.649, t-test p < 0.001).
This table shows molecular features associated with FKBP7 in patient tissues and cancer cell lines. In patient samples, FKBP7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
